Education
About Us
Working with TipRanks
Follow Us
Nanexa AB (SE:NANEXA)
:NANEXA
Top Page
Nanexa AB
(Frankfurt:NANEXA)
46Neutral
Nanexa AB (NANEXA) vs. S&P 500 (SPY)
Market Cap
kr298.53M
Dividend YieldN/A
Average Volume (3M)692.17K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-32.60%
EPS Growth73.04%
CountrySE
Employees13
SectorHealthcare
Sector Strength38
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding135,695,630
10 Day Avg. Volume1,145,944
30 Day Avg. Volume692,175
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Nanexa AB Business Overview & Revenue Model
Company DescriptionNanexa AB (NANEXA) is a Swedish pharmaceutical company focused on the development of innovative drug delivery systems. The company's core technology, PharmaShell®, is a proprietary drug delivery platform that enhances the efficacy and safety of pharmaceutical compounds. Nanexa operates in the biotechnology and pharmaceutical sectors, collaborating with various pharmaceutical companies to provide advanced solutions for drug formulation and delivery.
How the Company Makes MoneyNanexa AB generates revenue through partnerships and licensing agreements with pharmaceutical companies interested in utilizing its PharmaShell® technology. These collaborations often involve upfront payments, milestone payments, and royalties based on the commercial success of the drugs developed using their platform. Additionally, Nanexa may engage in research and development service agreements where they provide expertise in drug formulation and delivery to other entities. Key factors contributing to their earnings include the successful development and commercialization of drugs using PharmaShell®, as well as the establishment of strategic partnerships in the pharmaceutical industry.
Nanexa AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 24.36M | 29.33M | 2.86M | 2.37M | 2.37M | Gross Profit |
| 46.69M | 59.16M | 3.40M | 4.31M | 20.86M | EBIT |
| -26.06M | -76.63M | -58.30M | -35.82M | -21.49M | EBITDA |
| -13.69M | -70.79M | -53.86M | -32.92M | -19.02M | Net Income Common Stockholders |
| -24.91M | -76.40M | -58.57M | -36.00M | -21.74M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 10.29M | 65.17M | 81.18M | 105.66M | 12.69M | Total Assets |
| 91.82M | 132.26M | 170.19M | 165.00M | 53.69M | Total Debt |
| 2.20M | 4.03M | 6.27M | 3.83M | 3.89M | Net Debt |
| -8.10M | -11.14M | -74.91M | -101.83M | -8.80M | Total Liabilities |
| 20.90M | 36.43M | 61.10M | 13.70M | 10.34M | Stockholders Equity |
| 70.92M | 95.83M | 109.10M | 151.29M | 43.35M |
| Cash Flow | Free Cash Flow | |||
| -54.55M | -76.91M | -43.29M | -50.92M | -37.63M | Operating Cash Flow |
| -26.43M | -42.66M | -7.87M | -25.13M | -16.83M | Investing Cash Flow |
| -28.12M | -34.25M | -35.42M | -25.79M | -20.80M | Financing Cash Flow |
| -327.00K | 60.89M | 18.81M | 143.89M | 38.94M |
Nanexa AB Technical Analysis
Positive
1.94
Price Trends
1.36
Positive
1.58
Positive
1.60
Positive
Market Momentum
0.23
Negative
68.93
Neutral
62.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Positive. The current price of 1.94 is above the 20-day moving average (MA) of 1.65, above the 50-day MA of 1.36, and above the 200-day MA of 1.60, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 68.93 is Neutral, neither overbought nor oversold. The STOCH value of 62.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:NANEXA.
Nanexa AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
46 Neutral | kr298.53M | ― | -32.52% | ― | -32.60% | 73.04% | |
44 Neutral | €110.89M | ― | -151.10% | ― | 230.57% | 46.64% | |
43 Neutral | €433.36M | ― | -103.04% | ― | ― | 39.92% | |
41 Neutral | kr129.70M | ― | -153.78% | ― | -85.08% | -10.21% | |
32 Underperform | kr129.66M | ― | -186.40% | ― | ― | 24.47% |
* Healthcare Sector Average
Performance Comparison
SE:NANEXA
Nanexa AB
1.93
0.98
104.03%
SE:ACE
Ascelia Pharma AB
3.74
-2.68
-41.81%
SE:ACTI
Active Biotech AB
0.12
-0.10
-45.61%
SE:KLAR
Klaria Pharma Holding AB
0.90
0.46
104.10%
SE:NICA
Nanologica AB
1.27
-4.95
-79.66%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.